Peptides for Joints, Tendons and Ligaments 2026: BPC-157, TB-500 and Regeneration Mechanisms

In short

Peptides for joints are represented in the research literature primarily by the pair BPC-157 and TB-500, to which more complex models add GHK-Cu (a copper peptide for the collagen matrix) and Thymosin Alpha-1 (an immunomodulator in chronic inflammatory conditions).

Briefly:

• BPC-157, a 15-amino-acid pentadecapeptide with 200+ publications (Sikiric group, Zagreb). Principal mechanism in research tendon models: VEGFR2 angiogenesis and migration of fibroblasts / tenocytes.
• TB-500, a synthetic fragment of Thymosin β-4 (Goldstein 1981). In animal models it regulates the cytoskeleton via G-actin sequestration and mobilises endothelial progenitor cells.
• GHK-Cu, a copper tripeptide that in preclinical models stimulates the synthesis of collagen I/III and glycosaminoglycans (matrix of cartilage and connective tissues).
• Thymosin Alpha-1, an immunomodulator tested in research models of chronic inflammatory conditions (including autoimmune arthritides).

In the research literature, the BPC-157 + TB-500 combination is designated the “gold standard” for soft-tissue regeneration. This article summarises the mechanisms, published studies and differences between individual regenerative peptides for joints, tendons and ligaments, in the context of animal and cellular models, not human therapy.

1. Why classical NSAIDs do not work for deep joint problems

NSAIDs reach deep joint structures poorly and, more importantly, they suppress inflammation without supporting repair. Tendons and cartilage have limited blood supply, so a systemic COX inhibitor arrives in low concentration and does nothing for the matrix itself. Pain drops while the structural problem continues, which is why the research interest moved toward regenerative mechanisms.

Before moving on to peptides, it is worth understanding why research on regenerative molecules for joints is so active in the first place. The answer lies in the mechanistic limit of non-steroidal anti-inflammatory drugs (NSAIDs), molecules such as ibuprofen, diclofenac and naproxen.

NSAIDs act by blocking cyclooxygenase (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins. The result is alleviation of pain and swelling, but not tissue regeneration. An even more problematic finding appears in the published literature: NSAIDs may slow tendon healing and chondrogenesis. In research tendinopathy models it has repeatedly been demonstrated that COX-2 blockade reduces VEGF signalling, and therefore inhibits angiogenesis, which is required for reperfusion and the delivery of cells to the site of injury.

Peptides such as BPC-157 act in precisely the opposite direction, they activate the VEGFR2 pathway, support the formation of new vessels and promote tenocyte migration. This is a fundamental mechanistic distinction. NSAIDs suppress symptoms, whereas BPC-157 in research models supports remodelling of the extracellular matrix.

The second limit of NSAIDs concerns cartilage. Chondrocytes produce type II collagen and proteoglycans, which constitute hyaline cartilage. Chronic NSAIDs in several publications reduced proteoglycan synthesis by ~30–40 %. Peptides such as GHK-Cu, by contrast, stimulate the synthesis of collagen and glycosaminoglycans, the opposite direction.

This is why the research community over the past two decades has turned towards regenerative peptides for joints, tendons and ligaments. NSAIDs remain useful for acute relief, but for deep tissue remodelling research peptides are mechanistically more suitable candidates, at least in preclinical models.

2. BPC-157, 200+ studies on tissue regeneration

BPC-157 (Body Protection Compound-157) is undoubtedly the best-documented peptide for the healing of tendons and ligaments in the entire regenerative literature. Our detailed BPC-157 product page provides complete mechanisms and studies, here we focus on what is critical for the research on joints and tendons.

Discovery, Sikiric 1991, Zagreb

BPC-157 was isolated in the 1990s in Zagreb under the leadership of Professor Predrag Sikiric. The group sought an endogenous protective factor in the gastric mucosa, and in gastric juice found a larger protein from which they isolated a 15-amino-acid active fragment. The first key publication on the pentadecapeptide appeared in 1991, and the Sikiric group has since published more than 200 peer-reviewed studies.

15 amino acids, gastric juice

Molecular parameters of BPC-157:

• 15 amino acids (sequence GEPPPGKPADDAGLV)
• Molecular mass 1,419 Da
• CAS 137525-51-0
• Stable in gastric acid, which enables oral administration in research models
• Plasma half-life 4–6 minutes (based on animal data)

VEGFR2 angiogenesis + fibroblast migration

For research on peptides for tendons, this mechanistic pair is the most important:

1. Activation of VEGFR2 → angiogenesis. BPC-157 induces expression of the vascular endothelial growth factor receptor (VEGFR2/KDR) and triggers the MAPK/ERK cascade. Result: formation of new capillaries in damaged tissue. Tendons have notoriously poor vascularisation, the principal reason why they heal so slowly. The angiogenic effect of BPC-157 circumvents this limit.

2. FAK-paxillin cell migration. BPC-157 activates Focal Adhesion Kinase, the enzyme that couples the extracellular matrix with the internal cytoskeletal architecture. Via this pathway it induces the migration of fibroblasts, tenocytes and endothelial cells directly to the site of injury.

Chang et al. (2011) demonstrated in a rat model of Achilles tendon transection that BPC-157 significantly accelerates healing, including in tests of the mechanical strength of the healing tendon. Published in Journal of Applied Physiology PubMed 21030672.

Fractured bones, tendons, ligaments, GIT

BPC-157 has a very broad indication range in the preclinical literature:

• Tendons, Achilles tendon, patellar tendon, quadriceps tendon
• Ligaments, MCL models, collateral ligaments of the knee
• Bones, fracture models, osteoblast proliferation
• Muscles, contusion and transection models
• GIT lesions, NSAID and ethanol-induced damage
• Vascular healing, anastomoses, vessel ligation

For research on peptides for joints it is crucial that BPC-157 covers all four principal tissues of the joint apparatus, bone, ligament, tendon and muscle, which makes it a unique candidate for comprehensive regenerative models.

Clinical programme halted in Phase 2 (Crohn’s disease)

In the research community it is important to know why BPC-157 did not reach approval as a medicine. In Croatia, a clinical programme was conducted under the code PL-14736 for Crohn’s disease, it reached Phase 2, where it was terminated for financial reasons, not on account of a toxicity or efficacy signal. The molecule therefore remained in the research space and became the standard reference peptide for regenerative studies.

WADA 2022 S0

BPC-157 was added to the WADA Prohibited List on 1 January 2022, category S0 (Non-Approved Substances). WADA has developed LC-MS/MS detection methods. For professional athletes in regulated sports the ban applies. In the research context (RUO) it does not apply, but it is relevant when publishing results in sports science.

Complete parameters, purity, CoA and HPLC chromatograms are available on the BPC-157 product page.

3. TB-500, cytoskeletal reorganisation

TB-500 is the second pillar of research on peptides for tendons and joints. The molecule is a synthetic fragment of Thymosin β-4 (Tβ4), an endogenous human protein present in practically all cells. Detailed parameters are available on the TB-500 product page.

Fragment of Thymosin β4 (Allan Goldstein 1981)

Thymosin β-4 was isolated by Allan Goldstein in 1981 from the thymus. It was later established that Tβ4 is one of the most abundant proteins in mammalian cells overall, suggesting that its role would be fundamental. TB-500 is a synthetic 17-mer fragment (amino acids 4–23 of native Tβ4) that retains the principal biological activities of the full molecule.

G-actin sequestration

The principal mechanism of TB-500 is regulation of actin, the most important building block of the cellular cytoskeleton:

• Tβ4 binds monomeric G-actin and serves as its “storage molecule”
• When a cell receives a signal to migrate, divide or change shape, Tβ4 releases G-actin
• The cell can then dynamically reorganise its cytoskeleton, a necessary condition for healing

For research on joints and tendons this is critical, tenocytes and synovial cells must be able to migrate and change shape during healing. Without effective actin dynamics, remodelling comes to a halt.

Mobilisation of stem cells

In preclinical models, TB-500 induces expression of VEGF and chemoattractively mobilises endothelial progenitor cells (EPCs) and CD133+ stem cells from the bone marrow to sites of damage. For complex injuries (where local fibroblast migration alone is insufficient) this property is decisive.

Cardiac and cutaneous regeneration

TB-500 (respectively native Tβ4) has the strongest clinical data in the following areas:

• Cardiac regeneration, two Nature publications (Bock-Marquette 2004, Smart 2007), Phase 2 trial REGENERATE-1
• Cutaneous wound healing, notably diabetic ulcers
• Ophthalmology, Phase 2 programme TB4-Eye for dry eye
• Hepatic fibrosis, anti-fibrotic effect in preclinical models

Smart N. et al. (2007) in Nature demonstrated that Tβ4 mobilises adult epicardial progenitor cells and induces cardiac neovascularisation, PubMed 17108969. The key article by Goldstein AL., Hannappel E., Kleinman HK. (2005) in Trends in Molecular Medicine summarises Tβ4 as an actin-sequestering protein that “moonlights” as a regenerative factor, PubMed 16099219.

For tendons and ligaments, TB-500 is secondary (BPC-157 has more tendinous studies), but as a partner in combination it plays a key role.

4. Why the BPC-157 + TB-500 combination is the gold standard of regeneration research

The pairing is called canonical because the two mechanisms complement rather than duplicate each other. BPC-157 restores the vascular network through VEGFR2 and drives fibroblast migration; TB-500 sequesters G-actin and mobilises progenitor cells from bone marrow. One rebuilds the supply line, the other delivers the cells, which is why complex tendon models in the literature use both.

Whenever the regenerative literature mentions a “gold standard for tissue healing with peptides”, it almost invariably refers to the BPC-157 + TB-500 combination. The reason is purely mechanistic.

Complementary mechanisms (vascular + cytoskeletal)

Picture it this way: in the models, BPC-157 builds the vascular network and orchestrates the migration of local cells. Meanwhile, TB-500 brings in new cells from the bone marrow and ensures they can reorganise and integrate into the tissue. Without vessels there is nothing to bring stem cells to; without stem cells there is nothing to remodel the matrix. They are therefore complementary, not competing.

Sikiric group + independent studies

The combination is described in several publications from the Sikiric group, as well as in independent laboratories in Taiwan, China and the USA. Seiwerth S. et al. (2014) summarised the angiogenic profile of BPC-157 in Current Pharmaceutical Design, PubMed 23782243. The review by Sikiric P. et al. (2018) on the brain-gut axis and the pentadecapeptide BPC-157 in Current Pharmaceutical Design, PubMed 29945503, also discusses the synergy with Tβ4.

A detailed comparison of the two peptides is available in our guide BPC-157 vs TB-500.

5. GHK-Cu for the collagen matrix

GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) is a tripeptide that complements the BPC-157 + TB-500 pair wherever remodelling of the extracellular matrix is required. Detailed parameters and CoA are available on the GHK-Cu product page. In joint research it is therefore of interest from the connective tissue quality angle rather than as an anti-inflammatory.

Stimulation of collagen I/III synthesis

The key publication Pickart L. et al. (2015) in BioMed Research International summarises GHK-Cu as a natural modulator of multiple cellular pathways in skin regeneration, PubMed 26236730. In preclinical models GHK-Cu stimulates synthesis of type I and type III collagen, the principal structural proteins of tendons, ligaments and dermis.

Glycosaminoglycans (GAGs)

In addition to collagen, GHK-Cu also stimulates synthesis of glycosaminoglycans, long polysaccharides that form the principal hydrated matrix of cartilage. Without GAGs, cartilage loses elasticity and resistance to compressive loading. In osteoarthritis research, stimulation of GAGs is one of the central objectives.

Cartilage and dermal matrix

For regenerative peptides for joints, GHK-Cu is particularly relevant in the following models:

• Chondrogenesis, induction of chondrocytes, synthesis of cartilage matrix
• Collagen remodelling, in tendons and ligaments after damage
• Anti-fibrotic effects, in models of chronic soft-tissue pathology
• Dermal regeneration, the best-documented indication for GHK-Cu

As a mechanistic “building” peptide, GHK-Cu complements the signalling peptides BPC-157 and TB-500. Picture BPC-157 as the architect of the plan, TB-500 as the transporter of materials and GHK-Cu as the building material itself (collagen, GAGs).

6. Thymosin Alpha-1, chronic inflammatory conditions of joints

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus. Unlike BPC-157, TB-500 and GHK-Cu it is not primarily regenerative, it is immunomodulatory. In joint research it is relevant for models of chronic inflammatory conditions, including autoimmune arthritides. Details are available on the Thymosin Alpha-1 product page.

Immune modulation, cytokine balancing

In preclinical models, Tα1:

• Modulates T-cell activity (Th1/Th2 balancing)
• Reduces pro-inflammatory cytokines (IL-6, TNF-α)
• Supports the production of regulatory T cells (Tregs), which dampen autoimmune reactions
• Improves pathogen clearance via activation of dendritic cells

For joints, chronic immune dysregulation is critical, in rheumatoid arthritis, psoriatic arthritis and other autoimmune arthritides the excessive activity of Th17 and insufficient activity of Tregs lead to progressive destruction of cartilage.

Autoimmune arthritides, research models

In the research literature, Tα1 has been investigated in the following models:

• Collagen-induced arthritis (CIA) in mice, the standard model of rheumatoid arthritis
• Adjuvant arthritis in rats
• Models of psoriatic arthritis via the IL-23/IL-17 axis

In these models, Tα1 reduced the severity of joint involvement and modified the cytokine profile towards an anti-inflammatory state. It is not directly a regenerative peptide, but in a comprehensive research protocol for joint models with an autoimmune component it complements the mechanistic picture.

7. Comparison table: BPC-157 vs TB-500 vs GHK-Cu vs Thymosin α1

Set side by side the four differ in origin and target rather than in strength. BPC-157 and TB-500 are regenerative, GHK-Cu acts on the collagen matrix and Thymosin Alpha-1 is immunomodulatory. Only Thymosin Alpha-1 holds genuine approvals, which is the single most useful column in the table when judging evidence quality.

This is one of the few areas of research where none of the peptides is “the best”, each covers a different mechanistic angle, and in complex models they are combined.

8. Clinical studies in healing models (2018–2024)

Between 2018 and 2024 the healing model literature grew mainly on the animal side. TB-500 reached real Phase 2 trials, REGENERATE-1 and TB4-Eye, while BPC-157 accumulated preclinical replications without a completed human study. That gap matters: replication across laboratories is strong evidence of an effect, but it is not clinical evidence.

Over the past six years, research on peptides for tendons and joints has expanded from the originally dominant Sikiric group to laboratories in Taiwan, China, the USA and the EU. Key publication themes 2018–2024:

BPC-157 in tendon healing:

• Replication of the Achilles-tendon effect in independent laboratories (rats, mice)
• Tendinopathy models with VEGF blockade, confirmation of the mechanistic role of VEGFR2
• Compatibility with NSAIDs, BPC-157 in some models rescued healing that had been reduced by NSAIDs
• Extension from transection models to degenerative models (closer to clinical reality)

TB-500 in complex models:

• Musculoskeletal combined injuries (muscle + tendon + ligament)
• Reperfusion damage models
• Combined anti-fibrotic and pro-regenerative axis

GHK-Cu in cartilage:

• Chondrogenesis in vitro (cell lines)
• 3D scaffold models of cartilage regeneration
• Combinations with hyaluronate and growth factors

Thymosin Alpha-1 in autoimmunity:

• More detailed characterisation of Treg induction
• Models of psoriatic and reactive arthritis

For all four peptides, direct human clinical studies for indications of joints, tendons and ligaments are lacking, with the exception of the historical BPC-157 Phase 1/2 programme in Croatia, which was not directed specifically at tendons. Research remains preclinical, in animal models, isolated tissues and cell cultures.

9. How peptides are administered in tendon studies (subcutaneous, local)

In tendon studies peptides are given subcutaneously far more often than locally, because systemic administration is simpler, reproducible and still reaches the target in animal models. Direct intralesional injection appears where the model requires a defined local concentration. BPC-157 is the exception that is also studied orally, which is unusual for a peptide.

Routes of administration and dosing protocols in the research publications vary considerably depending on the peptide, tissue target and model:

BPC-157 in tendinous studies:

• Subcutaneous, most frequent, 10 ng/kg up to 10 µg/kg
• Intraperitoneal, comparable dosing, a classic in animal research
• Oral (drinking water), Staresinic and Chang demonstrated that oral administration also produces tendon healing
• Local (intra-tendinous infiltration), experimental, less standardised
• Duration: 14–28 days, daily dosing

TB-500 in regenerative models:

• Subcutaneous, standard, 150 µg/kg up to 6 mg/kg
• Intramuscular, for muscle models
• Intravenous, in the clinical studies of cardiac regeneration (REGENERATE-1)
• Topical, the TB4-Eye programme for dry eye
• Duration: 4–8 weeks, daily to weekly

GHK-Cu:

• Topical, dominant route (cutaneous models, with liposomes / carriers)
• Subcutaneous, for systemic regeneration
• Intra-articular, experimental in cartilage studies

Thymosin Alpha-1:

• Subcutaneous, 1.6 mg twice weekly (clinical standard in approved indications)
• Intravenous, experimental

The complete guide to reconstitution of lyophilisate and to dose calculation on an insulin syringe covers the practical aspects of preparing solutions in the research setting.

Note: The protocols cited are set within the context of published animal and cell-based studies. Direct extrapolations to human dosing are not validated in the literature. Molequa® sells peptides strictly for research use (RUO).

10. Frequently asked questions about peptides for joints

Which peptides are most researched for tendon and joint healing?

The largest number of published preclinical studies for peptides for joints, tendons and ligaments concerns BPC-157 (200+ studies, Sikiric group + independent laboratories). Second is TB-500 (respectively full Thymosin β-4), with two Nature publications. GHK-Cu dominates in collagen and cartilage models. Thymosin Alpha-1 is relevant for autoimmune arthritides. In models of complex regeneration, the BPC-157 + TB-500 combination is most frequently used.

What is the difference between BPC-157 and TB-500 in joint problems?

In research models of tendons and ligaments, BPC-157 is stronger, it has more direct tendinous studies (Chang 2011, Krivic 2006) and a dominant mechanism of VEGFR2 angiogenesis + FAK migration of tenocytes. TB-500 is stronger in models where mobilisation of stem cells from the bone marrow and cytoskeletal reorganisation are required, that is, more complex regenerative situations. In soft-tissue research they are most often combined.

Why does the Sikiric group recommend the BPC-157 + TB-500 combination?

The combination is mechanistically complementary. BPC-157 provides the vascular network (angiogenesis) and migration of local fibroblasts via VEGFR2 and FAK. TB-500 provides the supply of stem cells from the bone marrow and dynamics of the actin cytoskeleton. Without vessels there is nothing to bring stem cells to; without stem cells there is nothing to remodel the matrix. The combination is therefore designated by the Sikiric group and in independent publications as the “gold standard” for research on soft-tissue regeneration.

How long does tendon regeneration take in research models?

In most animal models of Achilles-tendon transection, the first histological changes (arrangement of collagen fibres, vascularisation) appear within 7–14 days, and mechanical strength increases over 14–28 days. Chang et al. (2011) demonstrated significant improvement over control in BPC-157 models as early as day 15. In the combined BPC-157 + TB-500 protocol, the studies are typically extended to 4–8 weeks. These are animal data, not human clinical data.

Are peptides for joints effective in osteoarthritis (research model)?

In osteoarthritis, the key question is cartilage regeneration, which is notoriously difficult because cartilage is avascular (without vessels) and chondrocytes have a low proliferative capacity. In research models, GHK-Cu stimulates the synthesis of type II collagen and glycosaminoglycans, the key components of the cartilage matrix. BPC-157 has more limited direct cartilage data but shows regenerative potential in models of subchondral bone and periarticular tissues. Direct human clinical studies for osteoarthritis are lacking.

Where can research peptides for regenerative studies be purchased in the EU?

The full range of peptides for sale is available in the Molequa® catalogue, HPLC/MS tested, with a certificate of analysis for every batch and EU delivery.

Molequa® offers BPC-157, TB-500, GHK-Cu and Thymosin Alpha-1 for laboratory scientific research in the EU with FedEx delivery 1–3 business days across Slovakia, the Czech Republic and the EU. All peptides are supplied in lyophilised form with a certificate of analysis (CoA), HPLC purity ≥ 99 %, MS confirmation of molecular identity and LAL endotoxin testing. Sale is restricted to qualified researchers (RUO).

What is the regulatory status of BPC-157 and TB-500?

Neither of these peptides is approved as a medicine, dietary supplement or cosmetic. Both progressed through clinical Phase 2 (BPC-157 for Crohn’s disease in Croatia, TB-500 in the REGENERATE-1 programme for cardiology), neither reached Phase 3, for financial reasons, not on account of a toxicity signal. WADA: BPC-157 has been in category S0 since 2022, TB-500 has long been in category S2. In the research context (RUO), WADA does not apply directly, but is relevant when publishing results in sports science.

11. Key scientific figures and citations

Peptides for joints, tendons and ligaments represent an active area of preclinical research that over the past 30 years has expanded from a single laboratory (Sikiric, Zagreb) to independent groups worldwide. The following key figures and references are provided:

“Pentadecapeptide BPC 157 exerts consistent regenerative effects across a broad spectrum of tissue injury models, including tendon, ligament, muscle, bone, and gastrointestinal mucosa, via VEGFR2-Akt-eNOS signalling and FAK-paxillin-mediated cell migration.” Sikiric P. et al. (2018), Current Pharmaceutical Design 24(18), PubMed 29945503

Statistics from preclinical/clinical literature

• BPC-157: 15 amino acids, 1,419 Da, isolated 1991 in Zagreb (P. Sikiric group), 200+ publications in PubMed
• TB-500: 17-mer fragment (amino acids 4–23) of native Thymosin β-4 (43 AA, 4,963 Da), first isolated by Goldstein in 1972, described as an actin-sequestering protein in 1981
• GHK-Cu: 3-amino-acid peptide (glycyl-histidyl-lysine) with a Cu²⁺ ion, isolated by Pickart in 1973 from human plasma
• Thymosin Alpha-1: 28 amino acids, isolated by Goldstein in 1972 from the thymus, an approved medicine (Zadaxin®) in several countries outside the EU for hepatitis B and immunodeficiencies
• Principal pathway of BPC-157: VEGFR2 → eNOS → angiogenesis, FAK-paxillin migration, NO modulation
• Principal pathway of TB-500/Tβ4: G-actin sequestration, activation of Akt/ILK, mobilisation of CD133+ progenitors
• Principal pathway of GHK-Cu: stimulation of the synthesis of collagen I/III, glycosaminoglycans, decorin
• Principal pathway of Tα1: modulation of T cells (Th1/Th2, Treg), activation of dendritic cells
• WADA status: BPC-157 = S0 (since 2022), TB-500 = S2, GHK-Cu = not on the Prohibited List, Tα1 = not on the Prohibited List

Reference sources (PubMed)

1. Sikiric P. et al. (2018). “Brain-gut Axis and Pentadecapeptide BPC 157.” Curr Pharm Des 24(18):1972–1989. PubMed 29945503
2. Chang CH. et al. (2011). “The promoting effect of pentadecapeptide BPC 157 on tendon healing.” J Appl Physiol 110(3):774–780. PubMed 21030672
3. Seiwerth S. et al. (2014). “BPC 157 and blood vessels.” Curr Pharm Des 20(7):1121–1125. PubMed 23782243
4. Goldstein AL., Hannappel E., Kleinman HK. (2005). “Thymosin β4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med 11(9):421–429. PubMed 16099219
5. Smart N. et al. (2007). “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.” Nature 445(7124):177–182. PubMed 17108969
6. Pickart L. et al. (2015). “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Biomed Res Int 2015:648108. PubMed 26236730

Scope of this article: This article summarises the scientific literature on peptides for joints, tendons and ligaments in research models and does not present therapeutic claims. The product is sold strictly for laboratory scientific research (RUO).

Frequently asked questions

Regulatory status

BPC-157, TB-500, GHK-Cu, Thymosin Alpha-1 and all Molequa® products are intended exclusively for research and scientific purposes (Research Use Only, RUO). They are not a medicine, dietary supplement, cosmetic product or foodstuff. They are not intended for human or animal consumption. Sale is restricted to qualified researchers, academic institutions and laboratories. Before any handling, the relevant scientific literature should be consulted and applicable legislation in the user’s jurisdiction should be observed. BPC-157 and TB-500 are prohibited by WADA for professional athletes.

Further reading

Molequa® product pages:

• BPC-157, complete guide
• TB-500, complete guide
• GHK-Cu, copper peptide for the collagen matrix
• Thymosin Alpha-1, immunomodulatory peptide

Related articles:

• BPC-157 vs TB-500, complete comparison of regenerative peptides
• What Are Peptides, introduction
• How to Reconstitute Lyophilisate, step by step

Practical guides:

• Dose calculation on an insulin syringe

Legal notice

BPC-157, TB-500, GHK-Cu, Thymosin Alpha-1 and all Molequa® products are intended exclusively for research and scientific purposes (Research Use Only, RUO). They are not a medicine, dietary supplement, cosmetic product or foodstuff. They are not intended for human or animal consumption. Sale is restricted to qualified researchers, academic institutions and laboratories. Before any handling, the relevant scientific literature should be consulted and applicable legislation in the user’s jurisdiction should be observed. BPC-157 and TB-500 are prohibited by WADA for professional athletes. The product is sold strictly for laboratory scientific research (RUO).

Author: Molequa® Research Team Publication date: July 2026 Last update: July 2026 Reading time: ~12 min